Cantor Fitzgerald Reiterates Overweight on Regeneron Pharmaceuticals, Maintains $800 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and maintains $800 price target.